Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with ...

As a result, the muscles become weak when a person performs repeated physical movements. The disease is neither contagious nor inherited but it is often misunderstood as a psychological issue or ...

SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized ...

Marla Black Morgan, MD, with Phoebe Neurology Associates, presented findings on a study into the diagnostic journey of ...

Ultomiris (ravulizumab-cwvz) is a brand-name infusion prescribed for myasthenia gravis. This article covers topics such as side effects, dosage, and how Ultomiris works. Ultomiris is an ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Researchers at AAN meeting discuss myasthenia gravis advances as J&J reports long-term data for nipocalimab, while argenx's ...

Rapper Lil Nas X has been admitted to the hospital after he said half of his face has become paralyzed. He shared the news on ...